Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 60

1.

Activity of ceftaroline against pathogens associated with community-acquired pneumonia collected as part of the AWARE surveillance program, 2015-2016.

Bae IG, Stone GG.

Diagn Microbiol Infect Dis. 2019 May 30:114843. doi: 10.1016/j.diagmicrobio.2019.05.015. [Epub ahead of print]

PMID:
31416647
2.

Ceftaroline fosamil as a potential treatment option for Staphylococcus aureus community-acquired pneumonia in adults.

Welte T, Kantecki M, Stone GG, Hammond J.

Int J Antimicrob Agents. 2019 Aug 9. pii: S0924-8579(19)30223-7. doi: 10.1016/j.ijantimicag.2019.08.012. [Epub ahead of print] Review.

3.

Safety and Efficacy of Ceftazidime-Avibactam in the Treatment of Children ≥3 Months to <18 Years With Complicated Urinary Tract Infection: Results from a Phase 2 Randomized, Controlled Trial.

Bradley JS, Roilides E, Broadhurst H, Cheng K, Huang LM, MasCasullo V, Newell P, Stone GG, Tawadrous M, Wajsbrot D, Yates K, Gardner A.

Pediatr Infect Dis J. 2019 Sep;38(9):920-928. doi: 10.1097/INF.0000000000002395.

PMID:
31335570
4.

Safety and Efficacy of Ceftazidime-Avibactam Plus Metronidazole in the Treatment of Children ≥3 Months to <18 Years With Complicated Intra-Abdominal Infection: Results From a Phase 2, Randomized, Controlled Trial.

Bradley JS, Broadhurst H, Cheng K, Mendez M, Newell P, Prchlik M, Stone GG, Talley AK, Tawadrous M, Wajsbrot D, Yates K, Zuzova A, Gardner A.

Pediatr Infect Dis J. 2019 Aug;38(8):816-824. doi: 10.1097/INF.0000000000002392.

PMID:
31306396
5.

Longitudinal analysis of the in vitro activity of ceftazidime-avibactam vs. Enterobacteriaceae, 2012-2016.

Ramalheira E, Stone GG.

J Glob Antimicrob Resist. 2019 Jul 8. pii: S2213-7165(19)30169-9. doi: 10.1016/j.jgar.2019.07.003. [Epub ahead of print]

PMID:
31295583
6.

Impact of EUCAST ceftaroline breakpoint change on the susceptibility of methicillin-resistant Staphylococcus aureus isolates collected from patients with complicated skin and soft-tissue infections.

Urbán E, Stone GG.

Clin Microbiol Infect. 2019 Apr 10. pii: S1198-743X(19)30125-9. doi: 10.1016/j.cmi.2019.03.023. [Epub ahead of print]

7.

A Retrospective Analysis of Probability of Target Attainment in Community-Acquired Pneumonia: Ceftaroline Fosamil Versus Comparators.

Cristinacce A, Wright JG, Stone GG, Hammond J, McFadyen L, Raber S.

Infect Dis Ther. 2019 Jun;8(2):185-198. doi: 10.1007/s40121-019-0243-4. Epub 2019 Apr 8.

8.

Characterization of β-Lactamase Content of Ceftazidime-Resistant Pathogens Recovered during the Pathogen-Directed Phase 3 REPRISE Trial for Ceftazidime-Avibactam: Correlation of Efficacy against β-Lactamase Producers.

Mendes RE, Castanheira M, Woosley LN, Stone GG, Bradford PA, Flamm RK.

Antimicrob Agents Chemother. 2019 May 24;63(6). pii: e02655-18. doi: 10.1128/AAC.02655-18. Print 2019 Jun.

PMID:
30910899
9.

In Vitro Activity of Ceftazidime-Avibactam against Clinical Isolates of Enterobacteriaceae and Pseudomonas aeruginosa Collected in Latin American Countries: Results from the INFORM Global Surveillance Program, 2012 to 2015.

Karlowsky JA, Kazmierczak KM, Bouchillon SK, de Jonge BLM, Stone GG, Sahm DF.

Antimicrob Agents Chemother. 2019 Mar 27;63(4). pii: e01814-18. doi: 10.1128/AAC.01814-18. Print 2019 Apr.

PMID:
30670424
10.

Dose Selection and Validation for Ceftazidime-Avibactam in Adults with Complicated Intra-abdominal Infections, Complicated Urinary Tract Infections, and Nosocomial Pneumonia.

Das S, Li J, Riccobene T, Carrothers TJ, Newell P, Melnick D, Critchley IA, Stone GG, Nichols WW.

Antimicrob Agents Chemother. 2019 Mar 27;63(4). pii: e02187-18. doi: 10.1128/AAC.02187-18. Print 2019 Apr. Review.

PMID:
30670413
11.

Ceftaroline fosamil doses and breakpoints for Staphylococcus aureus in complicated skin and soft tissue infections.

Das S, Li J, Iaconis J, Zhou D, Stone GG, Yan JL, Melnick D.

J Antimicrob Chemother. 2019 Feb 1;74(2):425-431. doi: 10.1093/jac/dky439.

12.
13.

Ceftazidime-Avibactam Susceptibility Breakpoints against Enterobacteriaceae and Pseudomonas aeruginosa.

Nichols WW, Stone GG, Newell P, Broadhurst H, Wardman A, MacPherson M, Yates K, Riccobene T, Critchley IA, Das S.

Antimicrob Agents Chemother. 2018 Oct 24;62(11). pii: e02590-17. doi: 10.1128/AAC.02590-17. Print 2018 Nov.

14.

In vitro activity of ceftazidime/avibactam against isolates of Pseudomonas aeruginosa collected in European countries: INFORM global surveillance 2012-15.

Kazmierczak KM, de Jonge BLM, Stone GG, Sahm DF.

J Antimicrob Chemother. 2018 Oct 1;73(10):2777-2781. doi: 10.1093/jac/dky267.

PMID:
30010951
15.

In vitro activity of ceftazidime/avibactam against isolates of Enterobacteriaceae collected in European countries: INFORM global surveillance 2012-15.

Kazmierczak KM, de Jonge BLM, Stone GG, Sahm DF.

J Antimicrob Chemother. 2018 Oct 1;73(10):2782-2788. doi: 10.1093/jac/dky266.

PMID:
30010894
16.

Clinical activity of ceftazidime/avibactam against MDR Enterobacteriaceae and Pseudomonas aeruginosa: pooled data from the ceftazidime/avibactam Phase III clinical trial programme.

Stone GG, Newell P, Gasink LB, Broadhurst H, Wardman A, Yates K, Chen Z, Song J, Chow JW.

J Antimicrob Chemother. 2018 Sep 1;73(9):2519-2523. doi: 10.1093/jac/dky204.

PMID:
29912399
17.

In Vitro Activity of Ceftazidime-Avibactam against Clinical Isolates of Enterobacteriaceae and Pseudomonas aeruginosa Collected in Asia-Pacific Countries: Results from the INFORM Global Surveillance Program, 2012 to 2015.

Karlowsky JA, Kazmierczak KM, Bouchillon SK, de Jonge BLM, Stone GG, Sahm DF.

Antimicrob Agents Chemother. 2018 Jun 26;62(7). pii: e02569-17. doi: 10.1128/AAC.02569-17. Print 2018 Jul.

18.

A Systematic Approach to the Selection of the Appropriate Avibactam Concentration for Use with Ceftazidime in Broth Microdilution Susceptibility Testing.

Bradford PA, Huband MD, Stone GG.

Antimicrob Agents Chemother. 2018 Jun 26;62(7). pii: e00223-18. doi: 10.1128/AAC.00223-18. Print 2018 Jul.

19.

In Vitro Activity of Ceftazidime-Avibactam against Isolates from Patients in a Phase 3 Clinical Trial for Treatment of Complicated Intra-abdominal Infections.

Stone GG, Newell P, Bradford PA.

Antimicrob Agents Chemother. 2018 Jun 26;62(7). pii: e02584-17. doi: 10.1128/AAC.02584-17. Print 2018 Jul.

20.

Molecular β-lactamase characterization of Gram-negative pathogens recovered from patients enrolled in the ceftazidime-avibactam phase 3 trials (RECAPTURE 1 and 2) for complicated urinary tract infections: Efficacies analysed against susceptible and resistant subsets.

Mendes RE, Castanheira M, Woosley LN, Stone GG, Bradford PA, Flamm RK.

Int J Antimicrob Agents. 2018 Aug;52(2):287-292. doi: 10.1016/j.ijantimicag.2018.04.001. Epub 2018 Apr 11.

PMID:
29654893
21.

Prevalence of mcr-type genes among colistin-resistant Enterobacteriaceae collected in 2014-2016 as part of the INFORM global surveillance program.

Wise MG, Estabrook MA, Sahm DF, Stone GG, Kazmierczak KM.

PLoS One. 2018 Apr 2;13(4):e0195281. doi: 10.1371/journal.pone.0195281. eCollection 2018.

22.

Assessment of 30/20-Microgram Disk Content versus MIC Results for Ceftazidime-Avibactam Tested against Enterobacteriaceae and Pseudomonas aeruginosa.

Sader HS, Rhomberg PR, Huband MD, Critchley IA, Stone GG, Flamm RK, Jones RN.

J Clin Microbiol. 2018 May 25;56(6). pii: e01960-17. doi: 10.1128/JCM.01960-17. Print 2018 Jun.

23.

Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial.

Torres A, Zhong N, Pachl J, Timsit JF, Kollef M, Chen Z, Song J, Taylor D, Laud PJ, Stone GG, Chow JW.

Lancet Infect Dis. 2018 Mar;18(3):285-295. doi: 10.1016/S1473-3099(17)30747-8. Epub 2017 Dec 16.

24.

Prevalence of carbapenem resistance and carbapenemase production among Enterobacteriaceae isolated from urine in the UK: results of the UK infection-Carbapenem Resistance Evaluation Surveillance Trial (iCREST-UK).

Woodford N, Xu-McCrae L, Mushtaq S, Wu HHT, Ellington MJ, Lancaster O, Davies F, Donaldson H, Rao GG, Verma A, Wareham DW, Ciesielczuk H, Stone GG, Irani PM, Bracher S, Hawkey PM.

J Antimicrob Chemother. 2018 Mar 1;73(3):698-702. doi: 10.1093/jac/dkx471.

PMID:
29253163
25.

Novel 3-fluoro-6-methoxyquinoline derivatives as inhibitors of bacterial DNA gyrase and topoisomerase IV.

Mitton-Fry MJ, Brickner SJ, Hamel JC, Barham R, Brennan L, Casavant JM, Ding X, Finegan S, Hardink J, Hoang T, Huband MD, Maloney M, Marfat A, McCurdy SP, McLeod D, Subramanyam C, Plotkin M, Reilly U, Schafer J, Stone GG, Uccello DP, Wisialowski T, Yoon K, Zaniewski R, Zook C.

Bioorg Med Chem Lett. 2017 Aug 1;27(15):3353-3358. doi: 10.1016/j.bmcl.2017.06.009. Epub 2017 Jun 3.

PMID:
28610977
26.

A randomised, double-blind, phase 3 study comparing the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem for complicated intra-abdominal infections in hospitalised adults in Asia.

Qin X, Tran BG, Kim MJ, Wang L, Nguyen DA, Chen Q, Song J, Laud PJ, Stone GG, Chow JW.

Int J Antimicrob Agents. 2017 May;49(5):579-588. doi: 10.1016/j.ijantimicag.2017.01.010. Epub 2017 Mar 29.

27.
28.

In vitro activity of ceftazidime/avibactam against urinary isolates from patients in a Phase 3 clinical trial programme for the treatment of complicated urinary tract infections.

Stone GG, Bradford PA, Yates K, Newell P.

J Antimicrob Chemother. 2017 May 1;72(5):1396-1399. doi: 10.1093/jac/dkw561.

PMID:
28088768
29.
30.

New Antimicrobial Agents  …  but No Susceptibility Tests!

Ambler JE, Krause KM, Steenbergen JN, Scangarella-Oman NE, Miller LA, Bhagwat SS, Serio AW, Chesnel L, Mahoney NM, Motyl MR, Critchley IA, Iaconis JP, Stone GG, Alder J, Xerri L, McCurdy SP, van Veenhuyzen DF, Grossman T, Echols RM, Williams G, Bradford PA.

Clin Infect Dis. 2016 Dec 1;63(11):1530-1531. Epub 2016 Aug 31. No abstract available.

PMID:
27581762
31.

Ceftazidime-avibactam Versus Doripenem for the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis: RECAPTURE, a Phase 3 Randomized Trial Program.

Wagenlehner FM, Sobel JD, Newell P, Armstrong J, Huang X, Stone GG, Yates K, Gasink LB.

Clin Infect Dis. 2016 Sep 15;63(6):754-762. doi: 10.1093/cid/ciw378. Epub 2016 Jun 16.

32.

Assessment of the In Vitro Activity of Ceftazidime-Avibactam against Multidrug-Resistant Klebsiella spp. Collected in the INFORM Global Surveillance Study, 2012 to 2014.

Hackel M, Kazmierczak KM, Hoban DJ, Biedenbach DJ, Bouchillon SK, de Jonge BL, Stone GG.

Antimicrob Agents Chemother. 2016 Jul 22;60(8):4677-83. doi: 10.1128/AAC.02841-15. Print 2016 Aug.

33.

Efficacy and Safety of Ceftazidime-Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-abdominal Infection: Results From a Randomized, Controlled, Double-Blind, Phase 3 Program.

Mazuski JE, Gasink LB, Armstrong J, Broadhurst H, Stone GG, Rank D, Llorens L, Newell P, Pachl J.

Clin Infect Dis. 2016 Jun 1;62(11):1380-1389. doi: 10.1093/cid/ciw133. Epub 2016 Mar 8.

34.

Activity of Ceftazidime-Avibactam against Extended-Spectrum- and AmpC β-Lactamase-Producing Enterobacteriaceae Collected in the INFORM Global Surveillance Study from 2012 to 2014.

Karlowsky JA, Biedenbach DJ, Kazmierczak KM, Stone GG, Sahm DF.

Antimicrob Agents Chemother. 2016 Apr 22;60(5):2849-57. doi: 10.1128/AAC.02286-15. Print 2016 May.

35.

β-Lactamase Characterization of Gram-Negative Pathogens Recovered from Patients Enrolled in the Phase 2 Trials for Ceftazidime-Avibactam: Clinical Efficacies Analyzed against Subsets of Molecularly Characterized Isolates.

Mendes RE, Castanheira M, Gasink L, Stone GG, Nichols WW, Flamm RK, Jones RN.

Antimicrob Agents Chemother. 2015 Dec 14;60(3):1328-35. doi: 10.1128/AAC.01173-15.

36.

NBTI 5463 is a novel bacterial type II topoisomerase inhibitor with activity against gram-negative bacteria and in vivo efficacy.

Dougherty TJ, Nayar A, Newman JV, Hopkins S, Stone GG, Johnstone M, Shapiro AB, Cronin M, Reck F, Ehmann DE.

Antimicrob Agents Chemother. 2014 May;58(5):2657-64. doi: 10.1128/AAC.02778-13. Epub 2014 Feb 24. Erratum in: Antimicrob Agents Chemother. 2014 Jul;58(7):4250.

37.

Avibactam reverts the ceftazidime MIC90 of European Gram-negative bacterial clinical isolates to the epidemiological cut-off value.

Flamm RK, Stone GG, Sader HS, Jones RN, Nichols WW.

J Chemother. 2014 Dec;26(6):333-8. doi: 10.1179/1973947813Y.0000000145. Epub 2013 Dec 6.

PMID:
24125508
38.

Novel quinoline derivatives as inhibitors of bacterial DNA gyrase and topoisomerase IV.

Mitton-Fry MJ, Brickner SJ, Hamel JC, Brennan L, Casavant JM, Chen M, Chen T, Ding X, Driscoll J, Hardink J, Hoang T, Hua E, Huband MD, Maloney M, Marfat A, McCurdy SP, McLeod D, Plotkin M, Reilly U, Robinson S, Schafer J, Shepard RM, Smith JF, Stone GG, Subramanyam C, Yoon K, Yuan W, Zaniewski RP, Zook C.

Bioorg Med Chem Lett. 2013 May 15;23(10):2955-61. doi: 10.1016/j.bmcl.2013.03.047. Epub 2013 Mar 21.

PMID:
23566517
39.

The discovery and structure-activity relationships leading to CE-156811, a difluorophenyl cyclopropyl fluoroether: a novel potent antibacterial analog derived from hygromycin A.

Le PT, Brickner SJ, Wade SK, Brighty K, Monahan R, Stone GG, Girard D, Finegan S, Duignan J, Schafer J, Maloney M, Zaniewski RP, Connolly AG, Liras J, Bordner J, Samardjiev I.

Bioorg Med Chem Lett. 2011 Jan 1;21(1):276-9. doi: 10.1016/j.bmcl.2010.11.022. Epub 2010 Nov 10.

PMID:
21115249
40.

Discovery of azetidinyl ketolides for the treatment of susceptible and multidrug resistant community-acquired respiratory tract infections.

Magee TV, Ripp SL, Li B, Buzon RA, Chupak L, Dougherty TJ, Finegan SM, Girard D, Hagen AE, Falcone MJ, Farley KA, Granskog K, Hardink JR, Huband MD, Kamicker BJ, Kaneko T, Knickerbocker MJ, Liras JL, Marra A, Medina I, Nguyen TT, Noe MC, Obach RS, O'Donnell JP, Penzien JB, Reilly UD, Schafer JR, Shen Y, Stone GG, Strelevitz TJ, Sun J, Tait-Kamradt A, Vaz AD, Whipple DA, Widlicka DW, Wishka DG, Wolkowski JP, Flanagan ME.

J Med Chem. 2009 Dec 10;52(23):7446-57. doi: 10.1021/jm900729s.

PMID:
19775168
41.

The arginine catabolic mobile element and staphylococcal chromosomal cassette mec linkage: convergence of virulence and resistance in the USA300 clone of methicillin-resistant Staphylococcus aureus.

Diep BA, Stone GG, Basuino L, Graber CJ, Miller A, des Etages SA, Jones A, Palazzolo-Ballance AM, Perdreau-Remington F, Sensabaugh GF, DeLeo FR, Chambers HF.

J Infect Dis. 2008 Jun 1;197(11):1523-30. doi: 10.1086/587907.

PMID:
18700257
42.

In vitro antibacterial activity of CE-156811, a novel analog derived from hygromycin A.

Stone GG, Girard D, Finegan S, Duignan J, Schafer J, Maloney M, Zaniewski RP, Brickner SJ, Wade SK, Le PT, Huband MD.

Antimicrob Agents Chemother. 2008 Jul;52(7):2663-6. doi: 10.1128/AAC.01326-07. Epub 2008 Apr 21.

43.

Design, synthesis and structure-activity relationships of 6-O-arylpropargyl diazalides with potent activity against multidrug-resistant Streptococcus pneumoniae.

Yong H, Gu YG, Clark RF, Marron T, Ma Z, Soni N, Stone GG, Nilius AM, Marsh K, Djuric SW.

Bioorg Med Chem Lett. 2005 May 16;15(10):2653-8. Erratum in: Bioorg Med Chem Lett. 2005 Jul 1;15(13):3313-4.

PMID:
15863336
44.

Synthesis and antibacterial activity of novel bifunctional macrolides.

Akritopoulou-Zanze I, Phelan KM, Marron TG, Yong H, Ma Z, Stone GG, Daly MM, Hensey DM, Nilius AM, Djuric SW.

Bioorg Med Chem Lett. 2004 Jul 16;14(14):3809-13.

PMID:
15203167
45.

Synthesis and antibacterial activity of 6-O-arylbutynyl ketolides with improved activity against some key erythromycin-resistant pathogens.

Keyes RF, Carter JJ, Englund EE, Daly MM, Stone GG, Nilius AM, Ma Z.

J Med Chem. 2003 May 8;46(10):1795-8.

PMID:
12723941
46.

PCR-oligonucleotide ligation assay for detection of point mutations associated with quinolone resistance in Streptococcus pneumoniae.

Bui MH, Stone GG, Nilius AM, Almer L, Flamm RK.

Antimicrob Agents Chemother. 2003 Apr;47(4):1456-9.

47.

Antimicrobial susceptibility and molecular characterization of community-acquired methicillin-resistant Staphylococcus aureus.

Almer LS, Shortridge VD, Nilius AM, Beyer JM, Soni NB, Bui MH, Stone GG, Flamm RK.

Diagn Microbiol Infect Dis. 2002 Jul;43(3):225-32.

PMID:
12106956
48.

Immunogenicity of chi4127 phoP- Salmonella enterica serovar Typhimurium in dogs.

McVey DS, Chengappa MM, Mosier DE, Stone GG, Oberst RD, Sylte MJ, Gabbert NM, Kelly-Aehle SM, Curtiss R.

Vaccine. 2002 Feb 22;20(11-12):1618-23.

PMID:
11858870
49.

Point mutations in the 23S rRNA gene of Helicobacter pylori associated with different levels of clarithromycin resistance.

Versalovic J, Osato MS, Spakovsky K, Dore MP, Reddy R, Stone GG, Shortridge D, Flamm RK, Tanaka SK, Graham DY.

J Antimicrob Chemother. 1997 Aug;40(2):283-6.

PMID:
9301997
50.

PCR-RFLP typing of ureC from Helicobacter pylori isolated from gastric biopsies during a European multi-country clinical trial.

Stone GG, Shortridge D, Flamm RK, Beyer J, Ghoneim AT, Tanaka SK.

J Antimicrob Chemother. 1997 Aug;40(2):251-6.

PMID:
9301991

Supplemental Content

Loading ...
Support Center